So far, few patients have
received the new drugs, as commercial health plans and Medicare wrestle with
how to cover the treatment
By Jonathan D. Rockoff
April 26, 2018 7:00
a.m. ET
The emergence of genetics-based medicines is pushing the
cost of treating certain diseases to new levels, forcing hospitals and health
insurers to reckon with how to cover total costs per patient approaching a
million dollars.
The therapies deliver new genes or genetically altered
cells to tackle some of the hardest-to-treat diseases, including in children.
They come at a high price: Novartis AG listed its newly approved cell therapy
for cancer at $475,000, while Gilead Sciences Inc. priced its rival drug at
$373,000.
No comments:
Post a Comment